🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed Non-Hodgkin Lymphoma

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study NCT05846763n/a1 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CD180 CART Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies NCT07284433Phase 1, Phase 213 sites📍 Chicago📍 Evanston📍 Providence AvenCell Therapeutics, Inc. · Tests: Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma NCT07121946Phase 16 sites📍 Duarte📍 St Louis📍 Buffalo LTZ Therapeutics, Inc. · Tests: LTZ-301, LTZ-301, LTZ-301 A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409Phase 1, Phase 211 sites📍 Santander📍 Salamanca📍 Barcelona IDP Discovery Pharma S.L. · Tests: IDP-121 Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas NCT06176690Phase 12 sites📍 Houston📍 Houston Baylor College of Medicine · Tests: C7R.CD30.CAR-EBVST cells Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma NCT07763210Phase 21 site📍 Nashville Vanderbilt-Ingram Cancer Center · Tests: Therapeutic Hydrocortisone, Cytarabine, Dexamethasone, Methylprednisolone, Cyclophosphamide Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease NCT05907759Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Daratumumab SC Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) NCT03936153Phase 223 sites📍 Beijing📍 Beijing📍 Beijing Xynomic Pharmaceuticals, Inc. · Tests: abexinostat SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites📍 Denver📍 Atlanta📍 Fairway Verismo Therapeutics · Tests: SynKIR-310 CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma NCT05054257Phase 11 site📍 Prague Institute of Hematology and Blood Transfusion, Czech Republ… · Tests: Autologous CAR19 T lymphocytes Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL NCT06874946Phase 1, Phase 21 site📍 Beijing Peking University People's Hospital · Tests: CD5-targeted CAR-T cells A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma NCT03460977Phase 185 sites📍 Tucson📍 Tucson📍 Tucson Pfizer · Tests: Mevrometostat (PF-06821497), Enzalutamide, Itraconazole Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma NCT07439653Phase 1, Phase 29 sites📍 Fullerton📍 Los Alamitos📍 Santa Monica TORL Biotherapeutics, LLC · Tests: TORL-5-700, TORL-5-700 at MTD/RP2D, TORL-5-700 at MTD/RP2D in combination with another agent An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies NCT07101705EARLY Phase 11 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: OriV508 Injection Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT06015880Phase 18 sites📍 Duarte📍 Sacramento📍 Tampa National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Lenalidomide, Mosunetuzumab, Polatuzumab Vedotin Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial NCT06948786Phase 21 site📍 Seattle University of Washington · Tests: Pirtobrutinib, Mosunetuzumab, Biospecimen Collection, Biopsy Procedure, Computed Tomography A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL NCT05514327NA1 site📍 Beijing Peking Union Medical College Hospital · Tests: ultra-fraction radiotherapy Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies NCT05887167Phase 11 site📍 Los Angeles Joshua Sasine, MD, PhD · Tests: autologous hematopoietic stem cells added to planned CAR T Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL NCT07013565Phase 21 site📍 Valhalla New York Medical College · Tests: Vinblastine (Velban), Brentuximab vedotin (Adcetris), Nivolumab (Opdivo) CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors NCT06365671Phase 21 site📍 Shanghai Ruijin Hospital · Tests: autologous stem-cell transplantation, Relmacabtagene autoleucel (relma-cel) GVM±R in Patients With Relapsed or Refractory Aggressive NHL. NCT06244368Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: GVM±R regimen Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies NCT06037018Phase 11 site📍 Tianjin CytoCares Inc · Tests: CC312 Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma NCT05077527Phase 17 sites📍 Duarte📍 Chicago📍 New York AIDS Malignancy Consortium · Tests: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma NCT07376642EARLY Phase 14 sites📍 Beijing📍 Beijing📍 Zhengzhou Suzhou Immunofoco Biotechnology Co., Ltd · Tests: IMV101 treatment Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma NCT06854445Phase 224 sites📍 Wuhu📍 Xiamen📍 Lanzhou Shanghai Chia Tai Tianqing Pharmaceutical Technology Develo… · Tests: TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T NCT06784726Phase 21 site📍 Seattle University of Washington · Tests: Odronextamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Ther… International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) NCT07476729Phase 321 sites📍 Vienna📍 Ghent📍 Prague Charite University, Berlin, Germany · Tests: Inotuzumab ozogamicin (INO), Blinatumomab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy